ArticleCritical care (London, England)2013
Serum activin A and B levels predict outcome in patients with acute respiratory failure: a prospective cohort study.
Article in Critical care (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Biomarker changes during long-term noninvasive ventilation in obesity hypoventilation syndrome: a prospective observational study.Sleep & breathing = Schlaf & Atmung · 2026Observational
- Role of IL-17 cytokines in tubal fibrosis and infertility due to salpingitis.Molecular biology reports · 2025Review
- Proteomic profiling of the local and systemic immune response to pediatric respiratory viral infections.mSystems · 2025Article
- Activin A and Follistatin Serum Concentrations in Breast Augmentation Patients.Plastic surgery (Oakville, Ont.) · 2023Article
- Serum levels of Activin A: Marker of insulin resistance and cardiovascular risk in prediabetics.Journal of family medicine and primary care · 2022Article
- Potential of Activin B as a Clinical Biomarker in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).Biomolecules · 2021Article
- Fibrosis: from mechanisms to medicines.Nature · 2020Review
- The Association between the Activin A Serum Level and Carotid Intima-Media Thickness in Chronic Kidney Disease Patients.International journal of nephrology · 2020Article
- TMEPAI/PMEPA1 Is a Positive Regulator of Skeletal Muscle Mass.Frontiers in physiology · 2020Article
- Rethinking ME/CFS Diagnostic Reference Intervals via Machine Learning, and the Utility of Activin B for Defining Symptom Severity.Diagnostics (Basel, Switzerland) · 2019Article
- Role of Activins in Hepcidin Regulation during Malaria.Infection and immunity · 2017Article
- Circulating Activin A predicts survival in cancer patients.Journal of cachexia, sarcopenia and muscle · 2017Article
- Activin Biology After Lung Transplantation.Transplantation direct · 2017Article
- Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study.Journal of translational medicine · 2017Observational
- Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis.Frontiers in pharmacology · 2017Review
- The Role of Activin A and B and the Benefit of Follistatin Treatment in Renal Ischemia-Reperfusion Injury in Mice.Transplantation direct · 2016Article
- Activins and Inhibins: Roles in Development, Physiology, and Disease.Cold Spring Harbor perspectives in biology · 2016Review
- Substantial Increases Occur in Serum Activins and Follistatin during Lung Transplantation.PloS one · 2016Article
- The immunoregulatory and fibrotic roles of activin A in allergic asthma.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2015Review
- The activin A antagonist follistatin inhibits cystic fibrosis-like lung inflammation and pathology.Immunology and cell biology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction30 day mortality in patients with Acute Respiratory Failure (ARF) is approximately 30%, defined as patients requiring ventilator support for more than 6 hours. Novel biomarkers are needed to predict patient outcomes and to guide potential future therapies. The activins A and B, members of the Transforming Growth Factor β family of proteins, and their binding protein, follistatin, have recently been shown to be important regulators of inflammation and fibrosis but no substantial data are available concerning their roles in ARF.
methodsSpecific assays for activin A, B and follistatin were used and the results analyzed according to diagnostic groups as well as according to standard measures in intensive care. Multivariable logistic regression was used to create a model to predict death at 90 days and 12 months from the onset of the ARF.
resultsSerum activin A and B were significantly elevated in most patients and in most of the diagnostic groups. Patients who had activin A and/or B concentrations above the reference maximum were significantly more likely to die in the 12 months following admission [either activin A or B above reference maximum: Positive Likelihood Ratio [LR+] 1.65 [95% CI 1.28-2.12, P = 0.00013]; both activin A and B above reference maximum: LR + 2.78 [95% CI 1.96-3.95, P < 0.00001]. The predictive model at 12 months had an overall accuracy of 80.2% [95% CI 76.6-83.3%].
conclusionsThe measurement of activin A and B levels in these patients with ARF would have assisted in predicting those at greatest risk of death. Given the existing data from animal studies linking high activin A levels to significant inflammatory challenges, the results from this study suggest that approaches to modulate activin A and B bioactivity should be explored as potential therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.